Overview Fundamentals API Earnings EOD API Sample Code Pricing

Santen Pharmaceutical Co. Ltd (SNPHF PINK) stock market data APIs

$11.89 0(0%) as of November 12, 2024
Price chart is built with Anychart

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co. Ltd Financial Data Overview

11.89
11.89
-
11.89
11.89
8.5341-12.5048
4 151 M
24.7708
349 M
302 563 M
0.15
0.0185
0.206
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SNPHF',
Type: 'Common Stock',
Name: 'Santen Pharmaceutical Co. Ltd',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000DQQB86',
ISIN: NULL,
CUSIP: NULL,
CIK: '1501108',
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: NULL,
IsDelisted: false,
}

Santen Pharmaceutical Co. Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 302 563 M
  • EBITDA 69 246 M
  • Earnings Per Share 0.48
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Santen Pharmaceutical Co. Ltd Earnings via APIs

  • Latest Release 2024-11-07
  • EPS/Forecast 0.18

Get Santen Pharmaceutical Co. Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com